Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity
Targeted therapies are effective in treating cancer, but success depends on identifying cancer vulnerabilities. In our study, we utilize small RNA sequencing to examine the impact of pathway activation on microRNA (miRNA) expression patterns. Interestingly, we discover that miRNAs capable of inhibit...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
17 October 2023
|
| In: |
Cell reports. Medicine
Year: 2023, Volume: 4, Issue: 10, Pages: 1-24 |
| ISSN: | 2666-3791 |
| DOI: | 10.1016/j.xcrm.2023.101200 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.xcrm.2023.101200 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2666379123003671 |
| Author Notes: | Alexander A. Wurm, Silke Brilloff, Sofia Kolovich, Silvia Schäfer, Elahe Rahimian, Vida Kufrin, Marius Bill, Zunamys I. Carrero, Stephan Drukewitz, Alexander Krüger, Melanie Hüther, Sebastian Uhrig, Sandra Oster, Dana Westphal, Friedegund Meier, Katrin Pfütze, Daniel Hübschmann, Peter Horak, Simon Kreutzfeldt, Daniela Richter, Evelin Schröck, Gustavo Baretton, Christoph Heining, Lino Möhrmann, Stefan Fröhling, Claudia R. Ball, and Hanno Glimm |
| Summary: | Targeted therapies are effective in treating cancer, but success depends on identifying cancer vulnerabilities. In our study, we utilize small RNA sequencing to examine the impact of pathway activation on microRNA (miRNA) expression patterns. Interestingly, we discover that miRNAs capable of inhibiting key members of activated pathways are frequently diminished. Building on this observation, we develop an approach that integrates a low-miRNA-expression signature to identify druggable target genes in cancer. We train and validate our approach in colorectal cancer cells and extend it to diverse cancer models using patient-derived in vitro and in vivo systems. Finally, we demonstrate its additional value to support genomic and transcriptomic-based drug prediction strategies in a pan-cancer patient cohort from the National Center for Tumor Diseases (NCT)/German Cancer Consortium (DKTK) Molecularly Aided Stratification for Tumor Eradication (MASTER) precision oncology trial. In conclusion, our strategy can predict cancer vulnerabilities with high sensitivity and accuracy and might be suitable for future therapy recommendations in a variety of cancer subtypes. |
|---|---|
| Item Description: | Gesehen am 16.04.2024 |
| Physical Description: | Online Resource |
| ISSN: | 2666-3791 |
| DOI: | 10.1016/j.xcrm.2023.101200 |